Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1992 Sep;107(1):215–221. doi: 10.1111/j.1476-5381.1992.tb14489.x

In vitro characterization of prostanoid FP-, DP-, IP- and TP-receptors on the non-pregnant human myometrium.

J Senior 1, R Sangha 1, G S Baxter 1, K Marshall 1, J K Clayton 1
PMCID: PMC1907618  PMID: 1422574

Abstract

1. Prostaglandin F (PGF), PGD, PGI and thromboxane A2 (TXA2) receptors have been pharmacologically characterized on the non-pregnant human myometrium in vitro in accordance with the receptor classification proposed by Coleman et al. (1984). The tools for the classification include both natural prostanoids, synthetic, selective analogues and antagonists where available. 2. The potent excitatory actions of the natural FP-receptor prostanoid, PGF2 alpha, and the synthetic analogue, fluprostenol, indicate the presence of FP-receptors mediating contraction on the human myometrium. 3. PGD2 produced a biphasic response consisting of excitation followed by relaxation of spontaneous activity of the myometrium. The selective DP-receptor agonists, BW245C, produced purely inhibitory responses illustrating the presence of inhibitory DP-receptors in this tissue. The inhibitory responses of both PGD2 and BW245C were antagonized by the competitive DP-receptor antagonist, BWA 868C, providing conclusive evidence for the existence of DP-receptors. 4. PGI2 produced a biphasic response similar to PGD2. Iloprost, the EP1/IP-receptor agonist also produced a biphasic response, whilst the IP-receptor selective agonist, cicaprost, caused inhibition only, suggesting that inhibitory IP-receptors exist in the non-pregnant human myometrium. 5. The TXA2-mimetic, U46619, produced marked stimulation of the non-pregnant human myometrium and was approximately equipotent to PGF2 alpha and fluprostenol in this effect. The actions of U46619 were competitively antagonized by the TP-receptor antagonist GR32191 showing that excitatory TP-receptors exist in this tissue.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
215

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ARUNLAKSHANA O., SCHILD H. O. Some quantitative uses of drug antagonists. Br J Pharmacol Chemother. 1959 Mar;14(1):48–58. doi: 10.1111/j.1476-5381.1959.tb00928.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Adelantado J. M., López Bernal A., Turnbull A. C. Topographical distribution of prostaglandin E receptors in human myometrium. Br J Obstet Gynaecol. 1988 Apr;95(4):348–353. doi: 10.1111/j.1471-0528.1988.tb06604.x. [DOI] [PubMed] [Google Scholar]
  3. Bauknecht T., Krahe B., Rechenbach U., Zahradnik H. P., Breckwoldt M. Distribution of prostaglandin E2 and prostaglandin F2 alpha receptors in human myometrium. Acta Endocrinol (Copenh) 1981 Nov;98(3):446–450. doi: 10.1530/acta.0.0980446. [DOI] [PubMed] [Google Scholar]
  4. Beasley R. C., Featherstone R. L., Church M. K., Rafferty P., Varley J. G., Harris A., Robinson C., Holgate S. T. Effect of a thromboxane receptor antagonist on PGD2- and allergen-induced bronchoconstriction. J Appl Physiol (1985) 1989 Apr;66(4):1685–1693. doi: 10.1152/jappl.1989.66.4.1685. [DOI] [PubMed] [Google Scholar]
  5. Chegini N., Rao C. V., Wakim N., Sanfilippo J. Prostaglandin binding to different cell types of human uterus: quantitative light microscope autoradiographic study. Prostaglandins Leukot Med. 1986 Apr;22(1):129–138. doi: 10.1016/0262-1746(86)90029-6. [DOI] [PubMed] [Google Scholar]
  6. Coleman R. A., Humphrey P. P., Kennedy I., Levy G. P., Lumley P. Comparison of the actions of U-46619, a prostaglandin H2-analogue, with those of prostaglandin H2 and thromboxane A2 on some isolated smooth muscle preparations. Br J Pharmacol. 1981 Jul;73(3):773–778. doi: 10.1111/j.1476-5381.1981.tb16814.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Coleman R. A., Kennedy I., Sheldrick R. L. New evidence with selective agonists and antagonists for the subclassification of PGE2-sensitive (EP) receptors. Adv Prostaglandin Thromboxane Leukot Res. 1987;17A:467–470. [PubMed] [Google Scholar]
  8. Crankshaw D. J., Crankshaw J., Branda L. A., Daniel E. E. Receptors for E type prostaglandins in the plasma membrane of nonpregnant human myometrium. Arch Biochem Biophys. 1979 Nov;198(1):70–77. doi: 10.1016/0003-9861(79)90396-5. [DOI] [PubMed] [Google Scholar]
  9. Crossley N. S. The synthesis and biological activity of potent, selective luteolytic prostaglandins. Prostaglandins. 1975 Jul;10(1):5–18. doi: 10.1016/0090-6980(75)90090-8. [DOI] [PubMed] [Google Scholar]
  10. Dong Y. J., Jones R. L., Wilson N. H. Prostaglandin E receptor subtypes in smooth muscle: agonist activities of stable prostacyclin analogues. Br J Pharmacol. 1986 Jan;87(1):97–107. doi: 10.1111/j.1476-5381.1986.tb10161.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Dyal R., Crankshaw D. J. The effects of some synthetic prostanoids on the contractility of the human lower uterine segment in vitro. Am J Obstet Gynecol. 1988 Feb;158(2):281–285. doi: 10.1016/0002-9378(88)90138-x. [DOI] [PubMed] [Google Scholar]
  12. Giannopoulos G., Jackson K., Kredentser J., Tulchinsky D. Prostaglandin E and F2 alpha receptors in human myometrium during the menstrual cycle and in pregnancy and labor. Am J Obstet Gynecol. 1985 Dec 15;153(8):904–910. doi: 10.1016/0002-9378(85)90704-5. [DOI] [PubMed] [Google Scholar]
  13. Giles H., Leff P., Bolofo M. L., Kelly M. G., Robertson A. D. The classification of prostaglandin DP-receptors in platelets and vasculature using BW A868C, a novel, selective and potent competitive antagonist. Br J Pharmacol. 1989 Feb;96(2):291–300. doi: 10.1111/j.1476-5381.1989.tb11816.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Giles H., Leff P. The biology and pharmacology of PGD2. Prostaglandins. 1988 Feb;35(2):277–300. doi: 10.1016/0090-6980(88)90093-7. [DOI] [PubMed] [Google Scholar]
  15. Hamid-Bloomfield S., Whittle B. J. Prostaglandin D2 interacts at thromboxane receptor-sites on guinea-pig platelets. Br J Pharmacol. 1986 Aug;88(4):931–936. doi: 10.1111/j.1476-5381.1986.tb16268.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Hofmann G. E., Rao C. V., Barrows G. H., Sanfilippo J. S. Topography of human uterine prostaglandin E and F2 alpha receptors and their profiles during pathological states. J Clin Endocrinol Metab. 1983 Aug;57(2):360–366. doi: 10.1210/jcem-57-2-360. [DOI] [PubMed] [Google Scholar]
  17. Kennedy I., Coleman R. A., Humphrey P. P., Levy G. P., Lumley P. Studies on the characterisation of prostanoid receptors: a proposed classification. Prostaglandins. 1982 Nov;24(5):667–689. doi: 10.1016/0090-6980(82)90036-3. [DOI] [PubMed] [Google Scholar]
  18. Lumley P., White B. P., Humphrey P. P. GR32191, a highly potent and specific thromboxane A2 receptor blocking drug on platelets and vascular and airways smooth muscle in vitro. Br J Pharmacol. 1989 Jul;97(3):783–794. doi: 10.1111/j.1476-5381.1989.tb12017.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Lye S. J., Challis J. R. Inhibition by PGI-2 of myometrial activity in vivo in non-pregnant ovariectomized sheep. J Reprod Fertil. 1982 Sep;66(1):311–315. doi: 10.1530/jrf.0.0660311. [DOI] [PubMed] [Google Scholar]
  20. Moncada S., Gryglewski R., Bunting S., Vane J. R. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature. 1976 Oct 21;263(5579):663–665. doi: 10.1038/263663a0. [DOI] [PubMed] [Google Scholar]
  21. Omini C., Pasargiklian R., Folco G. C., Fano M., Berti F. Pharmacological activity of PGI2 and its metabolite 6-oxo-PGF1alpha on human uterus and fallopian tubes. Prostaglandins. 1978 Jun;15(6):1045–1054. doi: 10.1016/0090-6980(78)90047-3. [DOI] [PubMed] [Google Scholar]
  22. Sanger G. J., Jackson A., Bennett A. A prostaglandin analogue which potently relaxes human uterus but not gut muscle. Eur J Pharmacol. 1982 Jun 16;81(1):141–143. doi: 10.1016/0014-2999(82)90613-6. [DOI] [PubMed] [Google Scholar]
  23. Schillinger E., Prior G., Speckenbach A., Wellershoff S. Receptor binding in various tissues of PGE2, PGF2 alpha and sulprostone, a novel PGE2-derivative. Prostaglandins. 1979 Aug;18(2):292–302. doi: 10.1016/0090-6980(79)90116-3. [DOI] [PubMed] [Google Scholar]
  24. Senior J., Marshall K., Sangha R., Baxter G. S., Clayton J. K. In vitro characterization of prostanoid EP-receptors in the non-pregnant human myometrium. Br J Pharmacol. 1991 Mar;102(3):747–753. doi: 10.1111/j.1476-5381.1991.tb12244.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Stürzebecher S., Haberey M., Müller B., Schillinger E., Schröder G., Skuballa W., Stock G., Vorbrüggen H., Witt W. Pharmacological profile of a novel carbacyclin derivative with high metabolic stability and oral activity in the rat. Prostaglandins. 1986 Jan;31(1):95–109. doi: 10.1016/0090-6980(86)90228-5. [DOI] [PubMed] [Google Scholar]
  26. Town M. H., Casals-Stenzel J., Schillinger E. Pharmacological and cardiovascular properties of a hydantoin derivative, BW 245 C, with high affinity and selectivity for PGD2 receptors. Prostaglandins. 1983 Jan;25(1):13–28. doi: 10.1016/0090-6980(83)90131-4. [DOI] [PubMed] [Google Scholar]
  27. Tynan S. S., Andersen N. H., Wills M. T., Harker L. A., Hanson S. R. On the multiplicity of platelet prostaglandin receptors. II. The use of N-0164 for distinguishing the loci of action for PGI2, PGD2, PGE2 and hydantoin analogs. Prostaglandins. 1984 May;27(5):683–696. doi: 10.1016/0090-6980(84)90007-8. [DOI] [PubMed] [Google Scholar]
  28. Wakeling A. E., Wyngarden L. J. Prostaglandin receptors in the human, monkey and hamster uterus. Endocrinology. 1974 Jul;95(1):55–64. doi: 10.1210/endo-95-1-55. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES